tetano
Editor, Senior Moderator
Cureus
. 2022 Oct 5;14(10):e29932.
doi: 10.7759/cureus.29932. eCollection 2022 Oct.
The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review
Nang I Kham[SUP] 1 2 [/SUP], Rabia Shahid[SUP] 1 [/SUP], Shaili S Naik[SUP] 1 3 [/SUP], Shivana Ramphall[SUP] 1 4 [/SUP], Swarnima Rijal[SUP] 1 [/SUP], Vishakh Prakash[SUP] 1 5 [/SUP], Heba Ekladios[SUP] 6 [/SUP], Jiya Mulayamkuzhiyil Saju[SUP] 1 7 8 [/SUP], Naishal Mandal[SUP] 1 3 [/SUP], Prachi Balani[SUP] 1 9 [/SUP]
Affiliations
Abstract
Thromboembolism is one of the most severe manifestations of coronavirus disease 2019 (COVID-19). Thrombotic complications have been reported even with the administration of thromboprophylaxis. This has led many experts to have variable opinions on the most effective prophylactic strategy and to anticipate the discovery of the ideal dosing of anticoagulation to reduce thromboembolic events and related mortality. We performed a systematic review to evaluate whether therapeutic-dose anticoagulation is superior to prophylactic-dose anticoagulation by comparing mortality rates, bleeding risks, and rates of thromboembolism. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to create our systematic review. Twenty-two records were collected from PubMed, PubMed Central (PMC), and Medical Literature Analysis and Retrieval System Online (MEDLINE), after which they undertook quality appraisals. A total of 124 studies were analyzed in six systematic reviews and meta-analyses, one pooled analysis, two multicenter retrospective cohort studies, one observational study, one retrospective chart review, one evidence-based protocol, and four narrative reviews.
Keywords: arteriovenous thromboembolism in sars-cov-2-infected patients; coronavirus disease 2019 (covid-19); critical hemorrhagic complications; prophylactic anticoagulation; risk of covid-19 mortality; therapeutic anticoagulation.
. 2022 Oct 5;14(10):e29932.
doi: 10.7759/cureus.29932. eCollection 2022 Oct.
The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review
Nang I Kham[SUP] 1 2 [/SUP], Rabia Shahid[SUP] 1 [/SUP], Shaili S Naik[SUP] 1 3 [/SUP], Shivana Ramphall[SUP] 1 4 [/SUP], Swarnima Rijal[SUP] 1 [/SUP], Vishakh Prakash[SUP] 1 5 [/SUP], Heba Ekladios[SUP] 6 [/SUP], Jiya Mulayamkuzhiyil Saju[SUP] 1 7 8 [/SUP], Naishal Mandal[SUP] 1 3 [/SUP], Prachi Balani[SUP] 1 9 [/SUP]
Affiliations
- PMID: 36381788
- PMCID: PMC9635931
- DOI: 10.7759/cureus.29932
Abstract
Thromboembolism is one of the most severe manifestations of coronavirus disease 2019 (COVID-19). Thrombotic complications have been reported even with the administration of thromboprophylaxis. This has led many experts to have variable opinions on the most effective prophylactic strategy and to anticipate the discovery of the ideal dosing of anticoagulation to reduce thromboembolic events and related mortality. We performed a systematic review to evaluate whether therapeutic-dose anticoagulation is superior to prophylactic-dose anticoagulation by comparing mortality rates, bleeding risks, and rates of thromboembolism. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to create our systematic review. Twenty-two records were collected from PubMed, PubMed Central (PMC), and Medical Literature Analysis and Retrieval System Online (MEDLINE), after which they undertook quality appraisals. A total of 124 studies were analyzed in six systematic reviews and meta-analyses, one pooled analysis, two multicenter retrospective cohort studies, one observational study, one retrospective chart review, one evidence-based protocol, and four narrative reviews.
Keywords: arteriovenous thromboembolism in sars-cov-2-infected patients; coronavirus disease 2019 (covid-19); critical hemorrhagic complications; prophylactic anticoagulation; risk of covid-19 mortality; therapeutic anticoagulation.